Trial Profile
A Phase 2 Randomized Study Comparing Radium Ra 223 Dichloride Plus Enzalutamide With Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Jan 2022
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Radium 223 chloride (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 01 Dec 2021 Results of an updated results on safety and efficacy with a median follow-up of 22 months and provide the findings on the secondary endpoints not previously reported published in the Oncologist
- 13 Feb 2021 Final safety and efficacy results of this trial presented at the 2021 Genitourinary Cancers Symposium
- 15 Feb 2020 Primary endpoint (Safety and feasibility of combining Ra-223+Enza) has been met as per results presented at the 2020 Genitourinary Cancers Symposium.